Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma

Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the pancreas * Unresectable locally advanced disease base on institutional standard criteria of unresectability disease following radical surgery. There is no evidence of metastatic disease in the major viscera and no peritoneal seeding * Patients with biliary or gastroduodenal obstruction must have drainage prior to starting chemoradiation * All malignant disease must be encompassable within a single irradiation field (15x15cm maximum) * All patients must have radiographically assessable disease * No previous irradiation to the planned field * Age of ≥ 18 years * performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) score * Required Entry Laboratory Parameters WBC count ≥ 1,000/mm3; hemoglobin level ≥ 7.5 g/dL; platelet count ≥ 100,000/mm3; total bilirubin ≤ 3.0 mg/dL (Patients with elevated bilirubin due to obstruction should be stented and their bilirubin should be decrease ≤ 3.0 mg/dL prior to study entry); creatinine ≤ 3.0 mg/dL * Oral intake (including J-tube feeding) of ≥ 1,500 calories/day should be maintained. * Signed informed consent form prior to study entry Exclusion Criteria: * There is evidence of metastasis in the major viscera or peritoneal seeding. * Age of \< 18 years * Previous history of RT adjacent to planned field * Poor performance status of 2 to 4 on the Eastern Cooperative Oncology Group (ECOG) score * Pregnant or breast feeding status * Previous history of uncontrolled other malignancies within 2 years